VRDN financials
Viridian Therapeutics (VRDN) financials: revenue, profit and margins by year and quarter, the balance sheet and cash flow.
VRDN income statement, yearly
| Year | Revenue | Gross profit | Operating income | Net income | EPS |
|---|---|---|---|---|---|
| 2025 | $70.85M | $70.85M | -$363.39M | -$342.60M | -3.32 |
| 2024 | $302.00K | $302.00K | -$299.04M | -$269.95M | -3.98 |
| 2023 | $314.00K | $314.00K | -$254.45M | -$237.73M | -5.31 |
| 2022 | $1.77M | $1.77M | -$134.30M | -$129.87M | -3.91 |
| 2021 | $2.96M | $2.96M | -$79.73M | -$79.41M | -6.66 |
| 2020 | $1.05M | -$27.25M | -$110.38M | -$110.72M | -31.20 |
- VRDN revenue was $70.85M in fiscal 2025, net income -$342.60M.
Updated 2026-11-07 11:53 UTC